REQUEST A DEMO
Total
USD $0.00
Search more companies

Ix Biopharma Ltd (Singapore)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Ix Biopharma Ltd Profile Updated: August 02, 2020
Buy our report for this company USD 29.95 Most recent financial data: 2020 Available in: English Download a sample report

iX Biopharma Ltd. is engaged in manufacturing and distribution of specialty pharmaceutical products with an expertise in drug delivery and formulation. The company's product portfolio includes Wafermine™, BnoX™, PheoniX™, WafeRest™, and Wafernyl™. iX Biopharma Ltd. is based in Singapore. The company was incorporated in 2008.

Legal Address
80 Robinson Road,#02-00
Singapore; Singapore; Postal Code: 068898

Contact Details: Purchase the Ix Biopharma Ltd report to view the information.

Website: http://www.ixbiopharma.com

Basic Information
Total Employees:
Purchase the Ix Biopharma Ltd report to view the information.
Outstanding Shares:
Purchase the Ix Biopharma Ltd report to view the information.
Financial Auditors:
Purchase the Ix Biopharma Ltd report to view the information.
Incorporation Date:
2004
Key Executives
Purchase this report to view the information.
Chairman/Director
Purchase this report to view the information.
Chairman/Director
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chief Financial Officer
Purchase this report to view the information.
Board Member
Ownership Details
Purchase this report to view the information.
25.45%
Company Performance
Financial values in the chart are available after Ix Biopharma Ltd report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency SGD. Absolute financial data is included in the purchased report.
Net sales revenue
46.8%
Total operating revenue
-83.22%
Operating profit (EBIT)
-260.74%
EBITDA
-311.69%
Net Profit (Loss) for the Period
-251.02%
Total assets
-36.36%
Total equity
-50.4%
Operating Profit Margin (ROS)
-646.17%
Net Profit Margin
-620.14%
Return on Equity (ROE)
-88.67%
Debt to Equity Ratio
19.84%
Quick Ratio
-4.3%
Cash Ratio
-4.55%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?